SG42355A1 - Stable liquid composition containing urate oxidase and lyophilized composition for its preparation - Google Patents

Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Info

Publication number
SG42355A1
SG42355A1 SG1996006306A SG1996006306A SG42355A1 SG 42355 A1 SG42355 A1 SG 42355A1 SG 1996006306 A SG1996006306 A SG 1996006306A SG 1996006306 A SG1996006306 A SG 1996006306A SG 42355 A1 SG42355 A1 SG 42355A1
Authority
SG
Singapore
Prior art keywords
urate oxidase
preparation
stable liquid
composition containing
liquid composition
Prior art date
Application number
SG1996006306A
Other languages
English (en)
Inventor
Claude Aleman
Alain Bayol
Thierry Breul
Patrice Dupin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG42355A1 publication Critical patent/SG42355A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • A61K38/443Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG1996006306A 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation SG42355A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9505606A FR2733914B1 (fr) 1995-05-11 1995-05-11 Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US08/644,163 US5811096A (en) 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Publications (1)

Publication Number Publication Date
SG42355A1 true SG42355A1 (en) 1997-08-15

Family

ID=26231954

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996006306A SG42355A1 (en) 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Country Status (24)

Country Link
US (1) US5811096A (da)
EP (1) EP0742013B1 (da)
JP (1) JP2950775B2 (da)
CN (1) CN1090972C (da)
AT (1) ATE183925T1 (da)
AU (1) AU710288B2 (da)
BR (1) BR1100337A (da)
CA (1) CA2175971C (da)
CZ (1) CZ290799B6 (da)
DE (1) DE69604009T2 (da)
DK (1) DK0742013T3 (da)
EA (1) EA000024B1 (da)
ES (1) ES2137635T3 (da)
FR (1) FR2733914B1 (da)
GR (1) GR3031896T3 (da)
HU (1) HU225147B1 (da)
IL (1) IL118171A (da)
NO (1) NO315261B1 (da)
NZ (1) NZ286554A (da)
PL (1) PL184135B1 (da)
SG (1) SG42355A1 (da)
SI (1) SI0742013T1 (da)
TW (1) TW420614B (da)
ZA (1) ZA963683B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
EP2158923B1 (en) * 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
CA2517310C (en) * 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
AU2004226666B9 (en) * 2003-04-02 2010-04-08 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
AU2004248931B2 (en) * 2003-06-20 2009-07-16 Ares Trading S.A. Freeze-dried FSH / LH formulations
DK3321359T3 (da) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc Variante former af uratoxidase og anvendelse deraf
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2008051178A2 (en) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
CN102807973A (zh) 2005-04-11 2012-12-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
CN1864744B (zh) * 2005-05-18 2010-09-29 杭州北斗生物技术有限公司 含有尿酸氧化酶的药用制剂
JP2008545665A (ja) * 2005-05-23 2008-12-18 ユニベルシテ ドゥ ジュネーブ 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928137A (en) * 1971-10-20 1975-12-23 Mallinckrodt Inc Reagent formulation for uric acid assay
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
JPS51104807A (en) * 1975-03-12 1976-09-17 Hitachi Ltd Teepurekoodano ootoribaasuseigyokairo
JPS5417027A (en) * 1977-07-07 1979-02-08 Canon Inc Image forming system
DE3126759A1 (de) * 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
JPS60224499A (ja) * 1984-04-23 1985-11-08 Toyobo Co Ltd 安定なウリカ−ゼ製剤
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
JPH0243471A (ja) * 1988-08-03 1990-02-14 Iwataro Moriyama 立体駐車装置
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
CA2130357A1 (en) 1992-02-18 1993-08-19 Doron Friedman Dry compositions for preparing submicron emulsions

Also Published As

Publication number Publication date
HU9601241D0 (en) 1996-07-29
CA2175971A1 (en) 1996-11-12
NO961915L (no) 1996-11-12
TW420614B (en) 2001-02-01
ES2137635T3 (es) 1999-12-16
EA000024B1 (ru) 1997-12-30
HUP9601241A3 (en) 2000-06-28
IL118171A (en) 2000-08-31
DE69604009T2 (de) 2000-04-06
EA199600024A2 (ru) 1996-12-30
JPH0925242A (ja) 1997-01-28
CN1090972C (zh) 2002-09-18
ATE183925T1 (de) 1999-09-15
DE69604009D1 (de) 1999-10-07
SI0742013T1 (en) 1999-12-31
EP0742013B1 (fr) 1999-09-01
DK0742013T3 (da) 2000-03-06
PL314147A1 (en) 1996-11-12
MX9601756A (es) 1997-07-31
NZ286554A (en) 1998-09-24
JP2950775B2 (ja) 1999-09-20
AU5213996A (en) 1996-11-21
FR2733914A1 (fr) 1996-11-15
NO961915D0 (no) 1996-05-10
PL184135B1 (pl) 2002-09-30
CZ290799B6 (cs) 2002-10-16
CA2175971C (en) 2003-12-30
HU225147B1 (en) 2006-07-28
US5811096A (en) 1998-09-22
FR2733914B1 (fr) 1997-08-01
CN1147961A (zh) 1997-04-23
IL118171A0 (en) 1996-09-12
EA199600024A3 (ru) 1997-03-31
NO315261B1 (no) 2003-08-11
AU710288B2 (en) 1999-09-16
HUP9601241A2 (en) 1997-04-28
CZ135096A3 (en) 1996-12-11
EP0742013A1 (fr) 1996-11-13
ZA963683B (en) 1997-11-10
BR1100337A (pt) 2000-07-25
GR3031896T3 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
ZA963683B (en) Stable liquid composition containing urate oxidase and lyophilized composition for its preparation.
IL117889A0 (en) Pharmaceutical compositions containing lipophilic compounds
AU7549696A (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
AU1777495A (en) Stable freeze-dried formulation comprising a protein; assay kit
CA2270088A1 (fr) Composition pharmaceutique a base d'estrogene et de progesterone
GR3033204T3 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins.
EP0353581A3 (en) Pharmaceutical compositions comprising selected lactobacillus strains
WO1995007108A3 (en) Formulations for delivery of osteogenic proteins
CA2274485A1 (en) Medicinal composition
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
EP1013274A3 (en) Composition comprising amoxycillin and clavulanic acid
AU1828192A (en) Megestrol acetate formulation
ITMI911580A1 (it) Preparazioni oftalmiche a rilascio protratto
CA2125643A1 (en) Pharmaceutical composition having analgesic activity
CA2103725A1 (en) Composition for use in transdermal administration
EP1413312A3 (en) Therapeutic human albumin having a low aluminium binding activity
CA2220103A1 (en) Composition comprising amoxycillin and clavulanic acid
EP0477143A3 (en) Pharmaceutical composition having a cicatrising effect
TH14725A (th) สารสูตรผสมชนิดใหม่
AU2453788A (en) A stable lyophilized form of (s)-(+)-bis-4,4'- (1-methyl-1,2-ethanediyl)2,6-piperazinedione and solutions thereof